ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

AstraZeneca, Hanmi Pharmaceutical and Aralez Pharmaceuticals side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

AstraZenecaHanmi PharmaceuticalAralez Pharmaceuticals
studies on the registry4,19719127
open to participants now298120
phase 3 studies under way20030
reach primary completion within a year16880
programswith a study of their own in two years119+5 named only12none read

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseAstraZenecaHanmi PharmaceuticalAralez Pharmaceuticals
Phase 1

AstraZeneca: 25 of its 119 programs at phase 1

  1. AZD4954phase 1
  2. AZD1613phase 1
  3. AZD1390phase 1
  4. Actinium Ac 225-DOTA-Anti-STEAP2 Monoclonal Antibody AZD2284phase 1
  5. ALXN2230phase 1

and 20 more — sign in to see them all

21%

Hanmi Pharmaceutical: 4 of its 12 programs at phase 1

  1. HIP2503phase 1
  2. HM17321phase 1
  3. IL-2 Mutein/Fc Fusion Protein HM16390phase 1
  4. RLD2606phase 1
33%
–
Phase 2

AstraZeneca: 47 of its 119 programs at phase 2

  1. AZD9550phase 2
  2. zadavotide guraxetanphase 2
  3. palacaparibphase 2
  4. Berzanoflastphase 2
  5. AZD7798phase 2

and 42 more — sign in to see them all

39%

Hanmi Pharmaceutical: 3 of its 12 programs at phase 2

  1. belvarafenibphase 2
  2. HM15275phase 2
  3. cobimetinibphase 2
25%
–
Phase 3

AstraZeneca: 28 of its 119 programs at phase 3

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3

and 23 more — sign in to see them all

24%

Hanmi Pharmaceutical: 5 of its 12 programs at phase 3

  1. efpeglenatidephase 3
  2. HCP1306phase 3
  3. HCP1803-4phase 3
  4. hip2602phase 3
  5. hpp2602-2phase 3
42%
–
Approved, new studies

AstraZeneca: 19 of its 119 programs at approved, new studies

  1. durvalumabapproved, new study
  2. acalabrutinibapproved, new study
  3. trastuzumab deruxtecanapproved, new study
  4. osimertinibapproved, new study
  5. anifrolumabapproved, new study

and 14 more — sign in to see them all

16%
00%–

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
AstraZeneca60 readouts · 16 phase 3

AstraZeneca, Nov ’26: 4 programs whose next study reaches primary completion

  1. Autologous dnTGF-BRII-armored Anti-STEAP2 CAR T-cells AZD0754phase 2 · Nov 24 · NCT06267729
  2. STEAP2-targeting Radioconjugate AZD2287phase 2 · Nov 24 · NCT06267729
  3. durvalumabapproved, new study · Nov 30 · NCT07081633
  4. tremelimumabphase 3 · Nov 30 · NCT07081633

AstraZeneca, Dec ’26: 7 programs whose next study reaches primary completion, 2 in phase 3

  1. eculizumabapproved, new study · Dec 7 · NCT06724809
  2. AZD3974phase 1 · Dec 8 · NCT07290283
  3. baxdrostatphase 3 · Dec 10 · NCT07222917
  4. dapagliflozinapproved, new study · Dec 10 · NCT07222917
  5. benralizumabapproved, new study · Dec 23 · NCT05692180

and 2 more — sign in to see them all

AstraZeneca, Jan ’27: 13 programs whose next study reaches primary completion, 6 in phase 3

  1. laroprovstatphase 3 · Jan 4 · NCT07000136
  2. anifrolumabapproved, new study · Jan 6 · NCT05925803
  3. monalizumabphase 3 · Jan 8 · NCT05221840
  4. oleclumabphase 3 · Jan 8 · NCT05221840
  5. datopotamab deruxtecanphase 3 · Jan 11 · NCT06417814

and 8 more — sign in to see them all

AstraZeneca, Feb ’27: 7 programs whose next study reaches primary completion, 3 in phase 3

  1. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3 · Feb 1 · NCT06530849
  2. trastuzumab deruxtecanapproved, new study · Feb 10 · NCT06271837
  3. Berzanoflastphase 2 · Feb 11 · NCT07215702
  4. acalabrutinibapproved, new study · Feb 15 · NCT02972840
  5. zibotentanphase 3 · Feb 18 · NCT06087835

and 2 more — sign in to see them all

AstraZeneca, Mar ’27: 4 programs whose next study reaches primary completion

  1. AZD7760phase 2 · Mar 8 · NCT06749457
  2. AZD4954phase 1 · Mar 17 · NCT07812077
  3. AZD0543phase 1 · Mar 24 · NCT07824622
  4. Anti-Claudin 18.2 Antibody-drug Conjugate AZD4360phase 2 · Mar 31 · NCT06921928

AstraZeneca, Apr ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. AZD1043phase 1 · Apr 9 · NCT07511205
  2. camizestrantphase 3 · Apr 20 · NCT05774951
  3. ombetoxabartphase 2 · Apr 20 · NCT07285213

AstraZeneca, May ’27: 5 programs whose next study reaches primary completion, 2 in phase 3

  1. rilvegostomigphase 3 · May 4 · NCT04379596
  2. Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492phase 2 · May 5 · NCT06916806
  3. AZD1613phase 1 · May 22 · NCT07228364
  4. Budesonideapproved, new study · May 31 · NCT07073950
  5. formoterolapproved, new study · May 31 · NCT07073950

AstraZeneca, Jun ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. tozorakimabphase 3 · Jun 7 · NCT06932263
  2. ravulizumabapproved, new study · Jun 25 · NCT07308574
  3. Anti-GPC3 T Cell-engaging Antibody AZD9793phase 2 · Jun 30 · NCT06795022

AstraZeneca, Jul ’27: 3 programs whose next study reaches primary completion

  1. ALXN1920phase 2 · Jul 2 · NCT07157787
  2. AZD2389phase 2 · Jul 7 · NCT07610837
  3. SC rilvegostomig + rHuphase 1 · Jul 19 · NCT07161414

AstraZeneca, Aug ’27: 4 programs whose next study reaches primary completion

  1. ALXN2230phase 1 · Aug 9 · NCT07352423
  2. AZD0240phase 1 · Aug 30 · NCT06218914
  3. SC durvalumab + rHuphase 1 · Aug 30 · NCT07391670
  4. AZD6793phase 2 · Aug 31 · NCT07082738

AstraZeneca, Sep ’27: 2 programs whose next study reaches primary completion

  1. palacaparibphase 2 · Sep 29 · NCT05123482
  2. puxitatug samrotecanphase 3 · Sep 29 · NCT05123482

AstraZeneca, Oct ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. opemalirsenphase 2 · Oct 4 · NCT06824987
  2. cevolisiranphase 2 · Oct 11 · NCT06744647
  3. tarperprumigphase 2 · Oct 11 · NCT07160608
  4. torvutatug samrotecanphase 3 · Oct 15 · NCT07402915
  5. sodium zirconium cyclosilicateapproved, new study · Oct 30 · NCT07944378
Hanmi Pharmaceutical6 readouts · 3 phase 3··

Hanmi Pharmaceutical, Jan ’27: 1 program whose next study reaches primary completion

  1. HM15275phase 2 · Jan 0 · NCT07205900

Hanmi Pharmaceutical, Feb ’27: 1 program whose next study reaches primary completion

  1. RLD2606phase 1 · Feb 5 · NCT07939087

Hanmi Pharmaceutical, Mar ’27: 1 program whose next study reaches primary completion

  1. HM17321phase 1 · Mar 0 · NCT07219589
·····

Hanmi Pharmaceutical, Sep ’27: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. hip2602phase 3 · Sep 0 · NCT07899073
  2. hpp2602-2phase 3 · Sep 0 · NCT07899073

Hanmi Pharmaceutical, Oct ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. HCP1803-4phase 3 · Oct 30 · NCT07660796
Aralez Pharmaceuticals0 readouts · 0 phase 3············
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

AstraZeneca

New programs 2

Reached a new phase 1

Study stopped 0

None

Primary completion later 23

Hanmi Pharmaceutical

New programs 3

  • RLD2606phase 1 · first study · Nov 10
  • hip2602phase 3 · first study · Oct 20 · Erectile Dysfunction
  • hpp2602-2phase 3 · first study · Oct 20 · Erectile Dysfunction

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Aralez Pharmaceuticals

No programs read for this company.

Where they overlap

Conditions where at least two of them have programs: 11 in all. A program counts in each condition its studies name most.

ConditionAstraZenecaHanmi PharmaceuticalAralez Pharmaceuticals
Carcinoma, Non-Small-Cell Lung2 of 3 · compare here

AstraZeneca in Carcinoma, Non-Small-Cell Lung: 16 programs

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. ceralasertibphase 3

and 11 more — sign in to see them all

Their studies: AstraZeneca’s studies of Carcinoma, Non-Small-Cell Lung in search

Hanmi Pharmaceutical in Carcinoma, Non-Small-Cell Lung: 1 program

  1. cobimetinibphase 2

Their studies: Hanmi Pharmaceutical’s studies of Carcinoma, Non-Small-Cell Lung in search

–
Neoplasms2 of 3 · compare here

AstraZeneca in Neoplasms: 6 programs

  1. saruparibphase 3
  2. ceralasertibphase 3
  3. Leucovorinphase 2
  4. Ramucirumabphase 2
  5. AZD1390phase 1

and 1 more — sign in to see them all

Their studies: AstraZeneca’s studies of Neoplasms in search

Hanmi Pharmaceutical in Neoplasms: 2 programs

  1. belvarafenibphase 2
  2. cobimetinibphase 2

Their studies: Hanmi Pharmaceutical’s studies of Neoplasms in search

–
Diabetes Mellitus, Type 22 of 3 · compare here

AstraZeneca in Diabetes Mellitus, Type 2: 5 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. AZD6793phase 2
  4. Elecoglipron Test formulation 1 Dose Aphase 1
  5. dapagliflozinapproved, new study

Their studies: AstraZeneca’s studies of Diabetes Mellitus, Type 2 in search

Hanmi Pharmaceutical in Diabetes Mellitus, Type 2: 2 programs

  1. efpeglenatidephase 3
  2. HM15275phase 2

Their studies: Hanmi Pharmaceutical’s studies of Diabetes Mellitus, Type 2 in search

–
Obesity2 of 3 · compare here

AstraZeneca in Obesity: 4 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. AZD9550phase 2
  4. AZD1043phase 1

Their studies: AstraZeneca’s studies of Obesity in search

Hanmi Pharmaceutical in Obesity: 3 programs

  1. efpeglenatidephase 3
  2. HM15275phase 2
  3. HM17321phase 1

Their studies: Hanmi Pharmaceutical’s studies of Obesity in search

–
Melanoma2 of 3 · compare here

AstraZeneca in Melanoma: 3 programs

  1. tremelimumabphase 3
  2. ceralasertibphase 3
  3. CD8-guided IL-2 Fusion Protein AZD6750phase 2

Their studies: AstraZeneca’s studies of Melanoma in search

Hanmi Pharmaceutical in Melanoma: 2 programs

  1. belvarafenibphase 2
  2. cobimetinibphase 2

Their studies: Hanmi Pharmaceutical’s studies of Melanoma in search

–
Neoplasm Metastasis2 of 3 · compare here

AstraZeneca in Neoplasm Metastasis: 3 programs

  1. saruparibphase 3
  2. camizestrantphase 3
  3. trastuzumab deruxtecanapproved, new study

Their studies: AstraZeneca’s studies of Neoplasm Metastasis in search

Hanmi Pharmaceutical in Neoplasm Metastasis: 1 program

  1. belvarafenibphase 2

Their studies: Hanmi Pharmaceutical’s studies of Neoplasm Metastasis in search

–
Hypercholesterolemia2 of 3 · compare here

AstraZeneca in Hypercholesterolemia: 2 programs

  1. laroprovstatphase 3
  2. rosuvastatinapproved, new study

Their studies: AstraZeneca’s studies of Hypercholesterolemia in search

Hanmi Pharmaceutical in Hypercholesterolemia: 1 program

  1. HCP1306phase 3

Their studies: Hanmi Pharmaceutical’s studies of Hypercholesterolemia in search

–
Hypertension2 of 3 · compare here

AstraZeneca in Hypertension: 2 programs

  1. baxdrostatphase 3
  2. rosuvastatinapproved, new study

Their studies: AstraZeneca’s studies of Hypertension in search

Hanmi Pharmaceutical in Hypertension: 1 program

  1. HCP1803-4phase 3

Their studies: Hanmi Pharmaceutical’s studies of Hypertension in search

–
Ovarian Neoplasms2 of 3 · compare here

AstraZeneca in Ovarian Neoplasms: 2 programs

  1. saruparibphase 3
  2. torvutatug samrotecanphase 3

Their studies: AstraZeneca’s studies of Ovarian Neoplasms in search

Hanmi Pharmaceutical in Ovarian Neoplasms: 1 program

  1. cobimetinibphase 2

Their studies: Hanmi Pharmaceutical’s studies of Ovarian Neoplasms in search

–
Colorectal Neoplasms2 of 3 · compare here

AstraZeneca in Colorectal Neoplasms: 1 program

  1. Leucovorinphase 2

Their studies: AstraZeneca’s studies of Colorectal Neoplasms in search

Hanmi Pharmaceutical in Colorectal Neoplasms: 1 program

  1. cobimetinibphase 2

Their studies: Hanmi Pharmaceutical’s studies of Colorectal Neoplasms in search

–
Diabetes Mellitus2 of 3 · compare here

AstraZeneca in Diabetes Mellitus: 1 program

  1. dapagliflozinapproved, new study

Their studies: AstraZeneca’s studies of Diabetes Mellitus in search

Hanmi Pharmaceutical in Diabetes Mellitus: 1 program

  1. efpeglenatidephase 3

Their studies: Hanmi Pharmaceutical’s studies of Diabetes Mellitus in search

–

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetAstraZenecaHanmi PharmaceuticalAralez Pharmaceuticals
GLP1RAZD9550efpeglenatiderule–
A target, or a pathogen for a vaccine, known for: AstraZeneca 68 of 119 · Hanmi Pharmaceutical 5 of 12 · Aralez Pharmaceuticals 0 of 0 programs (34 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (AstraZeneca: 5).